Devin (on for Brian Abrams)'s questions to Incyte Corp (INCY) leadership • Q1 2025
Question
Devin, on behalf of Brian Abrams, questioned the Q1 contribution of the Optum formulary change for Opzelura and inquired about ongoing efforts to improve patient access for both atopic dermatitis and vitiligo.
Answer
An Incyte executive explained that the Optum formulary addition improved commercial coverage to 94% and places Opzelura in a preferred position on two of the three major PBMs. They also noted that growth is similar across both indications and that the company continues to enhance patient services to improve accessibility.